{
  "id": 1011,
  "text": "Gynecol Oncol, 2019, 154(1):110-117.[50] HUH W K, JOURA E A, GIULIANO A R, et al.Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J].",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Gynecol Oncol, 2019, 154(1):110-117.[50] HUH W K, JOURA E A, GIULIANO A R, et al.Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J].\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据相关研究结果，九价人乳头瘤病毒疫苗对16至26岁女性的最终疗效和安全性表现令人满意。该疫苗通过覆盖九种高危型和低危型HPV亚型，显著降低与HPV相关的宫颈癌前病变和宫颈癌的发生风险。在长期随访中，疫苗显示出了较高的免疫原性（免疫反应能力），并且对于目标HPV型别的预防效果持续显著。\n\n在安全性方面，大多数接种者仅表现出轻微的局部反应（如注射部位疼痛、红肿），全身性不良反应（如轻微发热、疲劳）少见且大多为短暂性，不影响疫苗的使用推广。\n\n总体而言，九价HPV疫苗对16至26岁女性具有良好的预防效果，安全性与耐受性较好，这为宫颈癌的一级预防提供了有效手段。",
  "query": "宫颈癌预防中，九价人乳头瘤病毒疫苗对于16至26岁女性的最终疗效及安全性如何？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 宫颈癌预防中，九价人乳头瘤病毒疫苗对于16至26岁女性的最终疗效及安全性如何？\n\n<reference text>: Gynecol Oncol, 2019, 154(1):110-117.[50] HUH W K, JOURA E A, GIULIANO A R, et al.Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J].\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据相关研究结果，九价人乳头瘤病毒疫苗对16至26岁女性的最终疗效和安全性表现令人满意。该疫苗通过覆盖九种高危型和低危型HPV亚型，显著降低与HPV相关的宫颈癌前病变和宫颈癌的发生风险。在长期随访中，疫苗显示出了较高的免疫原性（免疫反应能力），并且对于目标HPV型别的预防效果持续显著。\n\n在安全性方面，大多数接种者仅表现出轻微的局部反应（如注射部位疼痛、红肿），全身性不良反应（如轻微发热、疲劳）少见且大多为短暂性，不影响疫苗的使用推广。\n\n总体而言，九价HPV疫苗对16至26岁女性具有良好的预防效果，安全性与耐受性较好，这为宫颈癌的一级预防提供了有效手段。"
}